Immuneering Corp

IMRX Nasdaq SEC CIK 1790340
Follow Immuneering Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$24.2M −61.7% vs same quarter last year
EPS, diluted −$0.37 +2.6% vs same quarter last year
Operating cash flow −$16.8M −40.1% vs same quarter last year
Operating income −$25.8M −67.7% vs same quarter last year
Net income by quarter
−$18.1M
−$15M
−$14.4M
−$15M
−$11.6M
−$13.5M
−$17.3M
−$24.2M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$80M−$60M−$40M−$20M$0$20MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25-−$56M
FY24-−$61M
FY23$0−$53.5M
FY22$317K−$50.5M
FY21$2.1M−$33.5M
FY20$2.3M−$17M
FY19--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−20000%−15000%−10000%−5000%0%5000%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY25---
FY24---
FY23---
FY2250.1%−16325.8%−15937.3%
FY2144.6%−1629.2%−1612.3%
FY2044.6%−739%−737.2%
FY19---
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$45.5M
FY24−$55.1M
FY23−$49.3M
FY22−$44.8M
FY21−$30.9M
FY20−$14.7M
FY19-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Immuneering
  • Healthcare median
−20000%−15000%−10000%−5000%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearImmuneeringHealthcare median
FY25-−30.6%
FY24-−47%
FY23-−58%
FY22−15937.3%−80.4%
FY21−1612.3%−71.8%
FY20−737.2%−62.2%
FY19-−46.2%